TY - JOUR
T1 - Prognostic factors for mature natural killer (NK) cell neoplasms
T2 - aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
AU - Suzuki, R.
AU - Suzumiya, J.
AU - Yamaguchi, M.
AU - Nakamura, S.
AU - Kameoka, J.
AU - Kojima, H.
AU - Abe, M.
AU - Kinoshita, T.
AU - Yoshino, T.
AU - Iwatsuki, K.
AU - Kagami, Y.
AU - Tsuzuki, T.
AU - Kurokawa, M.
AU - Ito, K.
AU - Kawa, K.
AU - Oshimi, K.
PY - 2009/10/22
Y1 - 2009/10/22
N2 - Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms. Patients and methods: We retrospectively analyzed 172 patients (22 with ANKL and 150 with ENKL). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas. Results: Complete remission rate for ENKL was 73% in stage I, but 15% in stage IV, which was consistent with that for ANKL (18%). The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P < 0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16). Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors. Using these four variables, an NK prognostic index was successfully constructed. Four-year overall survival of patients with zero, one, two and three or four adverse factors were 55%, 33%, 15% and 6%, respectively. Conclusion: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.
AB - Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms. Patients and methods: We retrospectively analyzed 172 patients (22 with ANKL and 150 with ENKL). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas. Results: Complete remission rate for ENKL was 73% in stage I, but 15% in stage IV, which was consistent with that for ANKL (18%). The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P < 0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16). Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors. Using these four variables, an NK prognostic index was successfully constructed. Four-year overall survival of patients with zero, one, two and three or four adverse factors were 55%, 33%, 15% and 6%, respectively. Conclusion: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.
KW - CD16
KW - Leukemia
KW - Lymphoma
KW - Natural killer cell
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=77953227669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953227669&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdp418
DO - 10.1093/annonc/mdp418
M3 - Article
C2 - 19850638
AN - SCOPUS:77953227669
VL - 21
SP - 1032
EP - 1040
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 5
ER -